JonesResearch downgraded Decibel Therapeutics (DBTX) to Hold from Buy after Decibel agreed to be acquired by Regeneron (REGN) for $4.00 per share along with a non-tradeable contingent value right, or CVR, to receive up to $3.50 per share in cash subsequent achievement of certain milestones related to DB-OTO.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on DBTX:
- Decibel Therapeutics (NASDAQ:DBTX) Skyrockets On Acquisition By Regeneron
- Decibel Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
- Regeneron to acquire Decibel Therapeutics for $4.00 per share plus CVR
Questions or Comments about the article? Write to editor@tipranks.com